Nektar presents a series of target-specific biomarkers

Nektar Therapeutics announced that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer. Etirinotecan pegol is a unique, next generation, targeted topoisomerase I inhibitor currently in Phase 3 clinical development as a potential treatment for patients with locally recurrent or metastatic breast cancer. The BEACON, BrEAst Cancer Outcomes with NKTR-102, Phase 3 Study is a randomized, open-label, international study that is evaluating single agent etirinotecan pegol in patients who have previously received an anthracycline, a taxane and capecitabine, ATC, versus a comparator arm consisting of an active single agent treatment of physician's choice, TPC.